 |
|
 |
- December 1, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Looking at New Evidence: Immediate Solutions to a Long-Term Problem"Dr. Steven V. Edelman (biography)
English - 2003-06-16 - 37 minutes
|
 | (44 slides) |
Summary :
Dr Edelman presents here new data supporting the rationale for treating insulin resistance and preserving beta cell function early in treatment. The RESULT (Rosiglitazone Early vs Sulfonylurea Titration) study was the first 2-year, randomized, double blind, parallel-group study comparing titration to maximum dose of SU versus half the maximum dose of SU plus rosiglitazone. This study showed that early addition of rosiglitazone to half the maximum dose of SU gets patients to an HbA1c below 7 and maintains durable glycemic control versus maximum dose of SU. Also the study of Rosiglitazone Added Early to 1 g Metformin showed improved insulin resistance, lowered HbA1c, good tolerability, and reductions in CRP and MMP-9 levels, and PAI-1 activity.
More information is available about C-Reactive Protein.
Learning objectives :
The participant will review data from two new studies: RESULT (Rosiglitazone Early vs Sulfonylurea Titration) and Rosiglitazone Added Early to 1 g Metformin:
- Early addition of rosiglitazone to half the maximum dose of SU is more effective than maximizing monotherapy with SU alone.
- Adding rosiglitazone to low dose metformin is more effective and more tolerable than high dose metformin alone.
- New data strengthens the rationale for targeting insulin resistance and preserving beta cell function early in treatment.
- Early diagnosis and treatment with drugs that improve insulin resistance may alter the natural history of type 2 diabetes.
Bibliographic references :
Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care. 1999 Dec;26(4):771-89.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
